@article{05553b670b3b42aba3f9597e423efa5b,
title = "Disseminating Knowledge in Intestinal Failure: Initial Report of the Learn Intestinal Failure Tele-ECHO (LIFT-ECHO) Project",
abstract = "Background: Intestinal failure (IF) is defined as an ultrarare disease, with an estimated prevalence of ∼25,000 cases in the US. There is a suspicion of disparities in outcomes in IF care, likely related to widespread lack of expertise. The Extension for Community Healthcare Outcomes (ECHO) model originally described by Dr Sanjeev Arora has been used to disseminate knowledge and best practices in many chronic diseases to improve outcomes. We examined our initial experience with using the ECHO model to disseminate learning in IF. Method: This is a retrospective review of the launch, growth, and geographic reach of the Learn Intestinal Failure TeleECHO (LIFT-ECHO) program using prospectively collected data. Results: The LIFT-ECHO program has achieved significant geographic reach and clinician engagement. The program has reached close to two-thirds of the states in the US and several countries outside. Clinician engagement in the learning program appears to be growing exponentially. Conclusion: It is feasible to use the ECHO model to disseminate knowledge in managing a rare disease like IF while maintaining fidelity to the proven model. Studies are underway to demonstrate direct benefit to patients.",
keywords = "Extension for Community Healthcare Outcomes, education, intestinal failure, outcomes, parenteral nutrition",
author = "Kishore Iyer and Marjorie Nisenholtz and David Gutierrez and Marion Winkler and Kelly Tappenden and Douglas Seidner and Kirby, {Donald F.} and Michelle Spangenburg and Ronald Potts and Anthony Bonagura and Joan Bishop and Lisa Metzger and Sanjeev Arora",
note = "Funding Information: Kishore Iyer is a scientific advisor for VectivBio Pharmaceuticals, Basel, Switzerland; Zealand Pharmaceuticals, Copenhagen, Denmark; and Hanmi Pharmaceuticals, Seoul, South Korea. Kishore Iyer receives grant support from Zealand Pharmaceuticals, Copenhagen, Denmark; and Takeda Pharmaceuticals, Lexington, MA. Kelly Tappenden is a scientific advisor for VectivBio Pharmaceuticals, Basel, Switzerland; Takeda Pharmaceuticals, Lexington, MA; and Baxter Pharmaceuticals, Deerfield, IL. Douglas Seidner is a consultant for VectivBio AG, Basel, Switzerland; and Zealand Pharma A/s, Copenhagen, Denmark. Douglas Seidner receives grant support from VectivBio AG, Basel, Switzerland; Zealand Pharma A/s, Copenhagen, Denmark; and Takeda Pharmaceuticals, Lexington, MA. Donald Kirby is a scientific advisor for VectivBio AG, Basel, Switzerland. Marion Winkler is a scientific advisor for Takeda Pharmaceuticals, Lexington, MA. All other authors report they no conflicts of interest to disclose. Funding Information: This work is supported by unrestricted educational grants from the Recanati Miller Transplant Institute (Intestinal Research Fund), Icahn School of Medicine at Mount Sinai, New York, NY; Oley Foundation, Albany, NY; Zealand Pharmaceuticals, Copenhagen, Denmark; and Takeda Pharmaceuticals, Cambridge, MA. Publisher Copyright: {\textcopyright} 2021 American Society for Parenteral and Enteral Nutrition",
year = "2021",
month = jul,
doi = "10.1002/jpen.2078",
language = "English",
volume = "45",
pages = "1108--1112",
journal = "Journal of Parenteral and Enteral Nutrition",
issn = "0148-6071",
publisher = "John Wiley & Sons Inc.",
number = "5",
}